Study Findings
Scientists at Anglia Ruskin University analyzed data from more than 90,000 patients across large international studies. They found that people treated with GLP-1 receptor agonists had a significantly lower risk of major cardiovascular events compared with those who received a placebo.
Long-Term Cardiovascular Benefits
The team reviewed 11 major cardiovascular outcome trials, with findings published in Cardiovascular Diabetology – Endocrinology Reports. The analysis showed that GLP-1 receptor agonists reduced the risk of serious cardiovascular events, including heart attack, stroke, and cardiovascular death, by about 13%.
Beyond Metabolic Benefits
GLP-1 receptor agonists are showing evidence of sustained cardiovascular effects beyond their established metabolic benefits. Long-term trial data suggest a measurable reduction in major adverse events, pointing to broader physiological impacts that extend over years of treatment.